Free Trial

CONMED (CNMD) Competitors

$73.59
+0.05 (+0.07%)
(As of 07/17/2024 ET)

CNMD vs. BLCO, PRCT, NARI, IRTC, NVCR, ESTA, AORT, BLFS, EYE, and AVNS

Should you be buying CONMED stock or one of its competitors? The main competitors of CONMED include Bausch + Lomb (BLCO), PROCEPT BioRobotics (PRCT), Inari Medical (NARI), iRhythm Technologies (IRTC), NovoCure (NVCR), Establishment Labs (ESTA), Artivion (AORT), BioLife Solutions (BLFS), National Vision (EYE), and Avanos Medical (AVNS). These companies are all part of the "medical equipment" industry.

CONMED vs.

CONMED (NYSE:CNMD) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

CONMED and Bausch + Lomb both received 25 outperform votes by MarketBeat users. However, 42.37% of users gave CONMED an outperform vote while only 39.06% of users gave Bausch + Lomb an outperform vote.

CompanyUnderperformOutperform
CONMEDOutperform Votes
25
42.37%
Underperform Votes
34
57.63%
Bausch + LombOutperform Votes
25
39.06%
Underperform Votes
39
60.94%

CONMED currently has a consensus price target of $102.50, indicating a potential upside of 39.29%. Bausch + Lomb has a consensus price target of $18.95, indicating a potential upside of 13.03%. Given CONMED's stronger consensus rating and higher possible upside, equities analysts plainly believe CONMED is more favorable than Bausch + Lomb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CONMED
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Bausch + Lomb
0 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.58

CONMED has a net margin of 6.53% compared to Bausch + Lomb's net margin of -7.81%. CONMED's return on equity of 13.78% beat Bausch + Lomb's return on equity.

Company Net Margins Return on Equity Return on Assets
CONMED6.53% 13.78% 4.86%
Bausch + Lomb -7.81%3.60%1.94%

CONMED has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

In the previous week, CONMED and CONMED both had 2 articles in the media. CONMED's average media sentiment score of 1.74 beat Bausch + Lomb's score of 0.59 indicating that CONMED is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CONMED
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Bausch + Lomb
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

11.1% of Bausch + Lomb shares are held by institutional investors. 6.8% of CONMED shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CONMED has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$1.24B1.82$64.46M$2.6128.20
Bausch + Lomb$4.15B1.42-$260M-$0.96-17.47

Summary

CONMED beats Bausch + Lomb on 13 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNMD vs. The Competition

MetricCONMEDElectromedical equipment IndustryMedical SectorNYSE Exchange
Market Cap$2.27B$3.09B$5.32B$18.71B
Dividend Yield1.09%1.76%2.80%3.45%
P/E Ratio28.206.23109.6321.60
Price / Sales1.8251.382,109.4815.56
Price / Cash12.1475.1735.9220.69
Price / Book2.713.994.965.14
Net Income$64.46M$85.16M$110.49M$974.70M
7 Day Performance8.64%7.58%2.73%2.97%
1 Month Performance9.05%1.56%9.34%6.48%
1 Year Performance-45.18%-4.65%5.78%9.05%

CONMED Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLCO
Bausch + Lomb
1.8031 of 5 stars
1.80 / 5 stars
$16.66
+5.2%
$18.95
+13.8%
-18.7%$5.86B$4.15B-17.3512,500News Coverage
PRCT
PROCEPT BioRobotics
0.6835 of 5 stars
0.68 / 5 stars
$69.76
+4.4%
$62.60
-10.3%
+92.6%$3.59B$156.33M-32.91430Analyst Forecast
NARI
Inari Medical
2.3905 of 5 stars
2.39 / 5 stars
$57.98
+5.8%
$66.86
+15.3%
+1.7%$3.37B$493.63M-141.411,300Analyst Forecast
Insider Selling
IRTC
iRhythm Technologies
2.7957 of 5 stars
2.80 / 5 stars
$104.96
+6.5%
$130.78
+24.6%
+1.3%$3.26B$492.68M-24.812,000Analyst Forecast
NVCR
NovoCure
3.6293 of 5 stars
3.63 / 5 stars
$19.28
+7.2%
$31.88
+65.3%
-52.9%$2.07B$509.34M-10.651,453Upcoming Earnings
ESTA
Establishment Labs
1.1373 of 5 stars
1.14 / 5 stars
$48.23
-1.6%
$54.00
+12.0%
-33.2%$1.33B$165.15M-15.36960
AORT
Artivion
0.4746 of 5 stars
0.47 / 5 stars
$28.47
+0.0%
$28.33
-0.5%
+76.9%$1.19B$354M-118.631,500Short Interest ↑
BLFS
BioLife Solutions
0.6031 of 5 stars
0.60 / 5 stars
$23.50
+3.2%
$23.67
+0.7%
+11.6%$1.08B$143.27M-16.55440Analyst Forecast
News Coverage
Positive News
EYE
National Vision
3.9723 of 5 stars
3.97 / 5 stars
$13.64
-1.0%
$19.60
+43.7%
-41.2%$1.07B$2.13B-14.8313,998Short Interest ↑
Positive News
AVNS
Avanos Medical
2.1227 of 5 stars
2.12 / 5 stars
$22.07
+5.4%
N/A-10.0%$1.01B$673.30M-16.593,771Analyst Revision
News Coverage

Related Companies and Tools

This page (NYSE:CNMD) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners